Key result
Novel triglyceride-lowering agents including ApoC-III inhibitors advance in early clinical development for hypertriglyceridemia.
This review highlights emerging therapies for hypertriglyceridemia, including apolipoprotein C-III inhibitors and fibroblast growth 21 analogues, to address residual cardiovascular risk.
These agents remain investigational; leaves open their effect on cardiovascular outcomes.
Hypertriglyceridemia has been identified as a risk factor for cardiovascular disease and acute pancreatitis. To date, there are only few drug classes targeting triglyceride levels such as fibrates and ω-3 fatty acids. These agents are at times insufficient to address very high triglycerides and the residual cardiovascular risk in patients with mixed dyslipidemia. To address this unmet clinical need, novel triglyceride-lowering agents have been in different phases of early clinical development. In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.
No takes yet. Share an insight, caveat, or question.
Parthymos et al. (2022) conducted a review in Hypertriglyceridemia. Novel triglyceride-lowering agents (apolipoprotein C-III inhibitors, ω-3 fatty acids, fibroblast growth 21 analogues) was evaluated. Novel triglyceride-lowering agents, including apolipoprotein C-III inhibitors, ω-3 fatty acids, and fibroblast growth 21 analogues, are in early clinical development for hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: